Header Logo

SHI-MING TU

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jackson JC, Sanchez D, Johns AC, Campbell MT, Aydin AM, Gokden N, Maraboyina S, Muesse JL, Ward JF, Pisters LL, Zacharias NM, Guo CC, Tu SM. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med. 2024 Jun 12; 13(12). PMID: 38929965; PMCID: PMC11205088.
      Citations:    
    2. Zhuang TZ, Master V, Simon N, Flippot R, Buti S, Rodriguez PA, Castellano D, de Velasco G, Glover M, Adra N, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Lee JL, Stahlfeld C, Freeman D, Apolo AB, El Zarif T, Nassar AH, Pond GR, Nazha B, Niglio S, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Maruzzo M, Mittra A, Gheeya J, Yang Y, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Khaki AR, El-Am E, Mouhieddine TH, Patel V, Farolfi A, Milowsky MI, Appleman L, Kim JW, Choueiri TK, Spiess PE, Necchi A, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst. 2023 12 06; 115(12):1605-1615. PMID: 37563779; PMCID: PMC11032703.
      Citations: 3     Fields:    Translation:Humans
    3. Tu SM, Singh SR, Arnaoutakis K, Malapati S, Bhatti SA, Joon AY, Atiq OT, Pisters LL. Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers (Basel). 2022 Jul 09; 14(14). PMID: 35884406; PMCID: PMC9321703.
      Citations:    
    4. Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SM. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass. 2023 Jan; 4(1):81-87. PMID: 36569509; PMCID: PMC9766861.
      Citations:    
    5. Tu SM, Moran C, Norton W, Zacharias NM. Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. Semin Diagn Pathol. 2023 Jan; 40(1):63-68. PMID: 35729019.
      Citations:    Fields:    
    6. Tu SM, Guo CC, Chow DS, Zacharias NM. Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. Cancers (Basel). 2022 Mar 18; 14(6). PMID: 35326699; PMCID: PMC8946169.
      Citations:    
    7. Tu SM, Pisters LL. Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267646; PMCID: PMC8909197.
      Citations:    
    8. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5). PMID: 35267435; PMCID: PMC8909729.
      Citations:    
    9. Tu SM, Estecio MR, Lin SH, Zacharias NM. Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy? Cancers (Basel). 2022 Jan 27; 14(3). PMID: 35158923; PMCID: PMC8833524.
      Citations: 1     
    10. Hwang MJ, Hamza A, Zhang M, Tu SM, Pisters LL, Czerniak B, Guo CC. Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol. 2022 01 01; 46(1):11-17. PMID: 34334690; PMCID: PMC8671201.
      Citations: 1     Fields:    Translation:Humans
    11. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267. PMID: 34536949.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Tu SM, Zhang M, Wood CG, Pisters LL. Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers (Basel). 2021 Aug 09; 13(16). PMID: 34439162; PMCID: PMC8394880.
      Citations: 4     
    13. Teyateeti A, Teyateeti A, Ravizzini GC, Xu G, Tang C, Tu SM, Macapinlac HA, Lu Y. Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level = 0.5 ng/ml after multiple treatment failures. Am J Nucl Med Mol Imaging. 2021; 11(2):87-98. PMID: 34079638; PMCID: PMC8165728.
      Citations: 1     
    14. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358. PMID: 33824525.
      Citations: 3     Fields:    Translation:Humans
    15. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 10; 39(5):1405-1410. PMID: 33770291.
      Citations: 7     Fields:    Translation:Humans
    16. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21. PMID: 33742104; PMCID: PMC7979841.
      Citations: 2     
    17. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 07; 26(7):558-e1098. PMID: 33491277; PMCID: PMC8265349.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    18. Tu SM, Pisters LL. Curing Cancer: Lessons from a Prototype. Cancers (Basel). 2021 Feb 07; 13(4). PMID: 33562202; PMCID: PMC7915721.
      Citations: 1     
    19. Tu SM, Campbell M, Shah A, Logothetis CJ. Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers. J Cell Sci Ther. 2021; 12(6). PMID: 34367724; PMCID: PMC8341073.
      Citations: 2     
    20. Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14; 12(12). PMID: 33327406; PMCID: PMC7764868.
      Citations: 8     
    21. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306. PMID: 33279304.
      Citations: 4     Fields:    Translation:Humans
    22. Umbreit EC, McIntosh AG, Suk-Ouichai C, Segarra LA, Holland LC, Fellman BM, Williams SB, Thomas AZ, Tu SM, Pettaway CA, Pisters LL, Ward JF, Wood CG, Karam JA. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020 11 15; 126(22):4878-4885. PMID: 32940929; PMCID: PMC9379780.
      Citations: 1     Fields:    Translation:Humans
    23. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5. PMID: 32675015; PMCID: PMC10014037.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    24. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673. PMID: 32453443.
      Citations: 4     Fields:    Translation:Humans
    25. Pan T, Martinez M, Hubka KM, Song JH, Lin SC, Yu G, Lee YC, Gallick GE, Tu SM, Harrington DA, Farach-Carson MC, Lin SH, Satcher RL. Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo. Mol Cancer Ther. 2020 06; 19(6):1266-1278. PMID: 32220969; PMCID: PMC7272308.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    26. McIntosh AG, Tu SM. Editorial Comment. J Urol. 2020 06; 203(6):1154. PMID: 32176596.
      Citations:    
    27. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    28. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75. PMID: 31986451; PMCID: PMC7350510.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    29. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999. PMID: 31941830.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    30. Siddiqui BA, Zhang M, Pisters LL, Tu SM. Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S56-S65. PMID: 32055486; PMCID: PMC6995840.
      Citations: 3     
    31. Ho L, Pisters L, Tu SM. Rapidly enlarging abdominal mass in a patient with recurrent germ cell tumor. Clin Case Rep. 2019 Nov; 7(11):2285-2286. PMID: 31788307; PMCID: PMC6878095.
      Citations:    
    32. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443. PMID: 31515154; PMCID: PMC6858999.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    33. Li R, Duplisea JJ, Petros FG, Tu SM, Karam JA, Huynh TT, Ward JF, Gonz?lez GMN. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Eur Urol Oncol. 2021 08; 4(4):651-658. PMID: 31412007.
      Citations: 4     Fields:    Translation:Humans
    34. Ting J, Bell D, Ahmed S, Ying A, Waguespack SG, Tu SM, Weber R, Zafereo M. Primary Malignant Thyroid Teratoma: An Institutional Experience. Thyroid. 2019 02; 29(2):229-236. PMID: 30759052.
      Citations: 3     Fields:    Translation:Humans
    35. Walker TJ, Risendal B, Kegler MC, Friedman DB, Weiner BJ, Williams RS, Tu SP, Fernandez ME. Assessing Levels and Correlates of Implementation of Evidence-Based Approaches for Colorectal Cancer Screening: A Cross-Sectional Study With Federally Qualified Health Centers. Health Educ Behav. 2018 12; 45(6):1008-1015. PMID: 29991294; PMCID: PMC6226355.
      Citations: 7     Fields:    Translation:Humans
    36. Chahoud J, Zhang M, Pisters LL, Lin SC, Lin SH, Tu SM. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018 10; 16(5):325-327. PMID: 29807831.
      Citations: 1     Fields:    Translation:HumansCells
    37. Chahoud J, Zhang M, Shah A, Lin SH, Pisters LL, Tu SM. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol. 2018 05; 30(3):181-188. PMID: 29538040.
      Citations: 2     Fields:    Translation:Humans
    38. Fernandez ME, Walker TJ, Weiner BJ, Calo WA, Liang S, Risendal B, Friedman DB, Tu SP, Williams RS, Jacobs S, Herrmann AK, Kegler MC. Developing measures to assess constructs from the Inner Setting domain of the Consolidated Framework for Implementation Research. Implement Sci. 2018 03 27; 13(1):52. PMID: 29587804; PMCID: PMC5870186.
      Citations: 53     Fields:    Translation:Humans
    39. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589. PMID: 28730293.
      Citations: 2     Fields:    Translation:Humans
    40. Krist AH, Woolf SH, Hochheimer C, Sabo RT, Kashiri P, Jones RM, Lafata JE, Etz RS, Tu SP. Harnessing Information Technology to Inform Patients Facing Routine Decisions: Cancer Screening as a Test Case. Ann Fam Med. 2017 05; 15(3):217-224. PMID: 28483886; PMCID: PMC5422082.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    41. Msaouel P, Bilen MA, Zhang M, Campbell M, Wang J, Tu SM. Recent developments in the management of germ cell tumors. Curr Opin Oncol. 2017 May; 29(3):172-178. PMID: 28151756; PMCID: PMC5538942.
      Citations:    
    42. Guo Y, Fu JB, Guo H, Camp J, Shin KY, Tu SM, Palmer LJ, Yadav R. Postacute Care in Cancer Rehabilitation. Phys Med Rehabil Clin N Am. 2017 02; 28(1):19-34. PMID: 27912997.
      Citations: 1     Fields:    Translation:Humans
    43. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143; PMCID: PMC5349913.
      Citations: 14     Fields:    Translation:Humans
    44. Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, Vikram R, Tu SM, Corn PG, Kim J. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clin Genitourin Cancer. 2017 06; 15(3):e429-e435. PMID: 28038931; PMCID: PMC5446270.
      Citations: 4     Fields:    Translation:Humans
    45. Msaouel P, Zhang M, Tu SM. Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. Clin Genitourin Cancer. 2017 02; 15(1):e73-e77. PMID: 27692813; PMCID: PMC5292059.
      Citations:    Fields:    Translation:Humans
    46. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016; 4:36. PMID: 27330809; PMCID: PMC4915058.
      Citations: 31     Fields:    
    47. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785; PMCID: PMC5071733.
      Citations: 17     Fields:    Translation:HumansCells
    48. Tu SM, Bilen MA, Tannir NM. Personalised cancer care: promises and challenges of targeted therapy. J R Soc Med. 2016 Mar; 109(3):98-105. PMID: 26933155; PMCID: PMC4794967.
      Citations: 8     Fields:    Translation:Humans
    49. Tu SM, Bilen MA, Lin SH. Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis. Oncology (Williston Park). 2015 Jul; 29(7):490-2. PMID: 26178337.
      Citations: 1     Fields:    Translation:Humans
    50. Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ. Management of Clinical Stage I Testicular Cancer: How Should We Define Success? J Clin Oncol. 2015 Jul 10; 33(20):2321-2. PMID: 26033805.
      Citations: 1     Fields:    Translation:Humans
    51. Wu W, Liu X, Chaftari P, Cruz Carreras MT, Gonzalez C, Viets-Upchurch J, Merriman K, Tu SM, Dalal S, Yeung SC. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS One. 2015; 10(3):e0122047. PMID: 25822612; PMCID: PMC4379069.
      Citations: 13     Fields:    Translation:Humans
    52. Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM. Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Rep Oncol Med. 2015; 2015:471861. PMID: 25861496; PMCID: PMC4377453.
      Citations: 5     
    53. Tu SP, Young VM, Coombs LJ, Williams RS, Kegler MC, Kimura AT, Risendal BC, Friedman DB, Glenn BA, Pfeiffer DJ, Fernandez ME. Practice adaptive reserve and colorectal cancer screening best practices at community health center clinics in 7 states. Cancer. 2015 Apr 15; 121(8):1241-8. PMID: 25524651; PMCID: PMC4393345.
      Citations: 7     Fields:    Translation:Humans
    54. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8. PMID: 25347368; PMCID: PMC4400850.
      Citations: 2     Fields:    Translation:Humans
    55. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76. PMID: 25155428; PMCID: PMC4270821.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    56. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60. PMID: 24882673; PMCID: PMC4247811.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    57. Hamdi A, Mulanovich VE, Matin SF, Landon G, Sircar K, Tu SM, Nieto Y. Isolated renal mucormycosis in a transplantation recipient. J Clin Oncol. 2015 Apr 01; 33(10):e50-1. PMID: 24821884.
      Citations: 2     Fields:    Translation:Humans
    58. Tu SM, Bilen MA, Tannir NM. The scientific method: pillar and pitfall of cancer research. Cancer Med. 2014 Aug; 3(4):1035-7. PMID: 24711219; PMCID: PMC4303171.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    59. Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, Tu SM. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer. 2014 Aug; 12(4):e147-50. PMID: 24674785; PMCID: PMC4104212.
      Citations: 1     Fields:    Translation:Humans
    60. Som A, Xiao L, Zhu R, Guo CC, Xiao L, Rao P, Efstathiou E, Matin A, Tu SM. Clinically atypical seminomas with yolk sac tumor features. Can J Urol. 2013 Aug; 20(4):6860-7. PMID: 23930614.
      Citations: 1     Fields:    Translation:Humans
    61. Som A, Wen S, Tu SM. Stem cell origin of testicular seminoma. Clin Genitourin Cancer. 2013 Dec; 11(4):489-94. PMID: 23850550; PMCID: PMC3834099.
      Citations: 4     Fields:    Translation:HumansCells
    62. Tu SM. Cancer: a "stem-cell" disease? Cancer Cell Int. 2013 May 06; 13(1):40. PMID: 23647946; PMCID: PMC3651409.
      Citations: 10     
    63. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30. PMID: 23649003; PMCID: PMC3699964.
      Citations: 136     Fields:    Translation:Humans
    64. Bilen MA, Kim J, Wang H, Tu SM. Cixutumumab-associated pancolitis in a patient with prostate cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):207-10. PMID: 23083799; PMCID: PMC3579009.
      Citations:    Fields:    Translation:Humans
    65. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012 Oct 23; 107(9):1547-53. PMID: 23033003; PMCID: PMC3493771.
      Citations: 15     Fields:    Translation:Humans
    66. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. 2012 Aug 07; 107(4):646-51. PMID: 22805323; PMCID: PMC3419961.
      Citations: 4     Fields:    Translation:Humans
    67. Tu SM, Chen AH. Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol. 2012 Jun; 19(3):6268. PMID: 22704311.
      Citations:    Fields:    Translation:Humans
    68. Tu SM, Lin SH. Prostate cancer stem cells. Clin Genitourin Cancer. 2012 Jun; 10(2):69-76. PMID: 22421313; PMCID: PMC4141775.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    69. Yennurajalingam S, Atkinson B, Masterson J, Hui D, Urbauer D, Tu SM, Bruera E. The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med. 2012 Jan; 15(1):20-4. PMID: 22141432.
      Citations: 19     Fields:    Translation:Humans
    70. Staquicini FI, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W, Card?-Vila M, Setubal JC. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42. PMID: 22049339; PMCID: PMC3219136.
      Citations: 42     Fields:    Translation:HumansCells
    71. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2011 Dec; 9(2):81-8. PMID: 21958521; PMCID: PMC3641665.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    72. Bilen MA, General R, Tu SM. Prolonged remission of fulminant castrate-resistant prostate cancer: a case report. Clin Genitourin Cancer. 2011 Dec; 9(2):133-6. PMID: 21729684; PMCID: PMC3205279.
      Citations:    Fields:    Translation:Humans
    73. He XX, Tu SM, Lee MH, Yeung SJ. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011 Dec; 22(12):2640-2645. PMID: 21415239; PMCID: PMC3221513.
      Citations: 68     Fields:    Translation:Humans
    74. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96. PMID: 21290244.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    75. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol. 2012 Nov-Dec; 30(6):879-85. PMID: 20933444; PMCID: PMC3956468.
      Citations: 13     Fields:    Translation:Humans
    76. Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501. PMID: 20822932; PMCID: PMC3856193.
      Citations: 4     Fields:    Translation:Humans
    77. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51. PMID: 20551894; PMCID: PMC4993042.
      Citations: 4     Fields:    Translation:HumansCells
    78. Punar M, Tamboli P, Tu SM, Pisters L, Moran C, Czerniak BA, Guo CC, Contreras AL. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol. 2010 Jun; 41(6):832-7. PMID: 20153508; PMCID: PMC4163004.
      Citations: 7     Fields:    Translation:Humans
    79. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol. 2010 Mar; 65(4):811-5. PMID: 20052472; PMCID: PMC4436674.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    80. Tu SM. Origin of cancers. Clinical perspectives and implications of a stem-cell theory of cancer. Cancer Treat Res. 2010; 154:v-239. PMID: 20645140.
      Citations: 19     Fields:    Translation:HumansCells
    81. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. PMID: 19887483; PMCID: PMC3644858.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    82. Guo CC, Punar M, Tu SM, Pisters L, Tamboli P, Czerniak B, Contreras AL. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009 Aug; 33(8):1173-8. PMID: 19561445; PMCID: PMC3812063.
      Citations: 19     Fields:    Translation:Humans
    83. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81. PMID: 19636008; PMCID: PMC4371138.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    84. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80. PMID: 19402048.
      Citations: 20     Fields:    Translation:Humans
    85. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24. PMID: 19414670; PMCID: PMC4371137.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    86. Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine. 2009 May; 10(5):414-22. PMID: 19442002.
      Citations: 15     Fields:    Translation:Humans
    87. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar 15; 115(6):1310-7. PMID: 19156903.
      Citations: 3     Fields:    Translation:Humans
    88. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009 Mar 15; 15(6):2130-9. PMID: 19276258; PMCID: PMC5806520.
      Citations: 34     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    89. Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu SM. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer. 2008 Sep; 6(2):128-30. PMID: 18824438.
      Citations:    Fields:    Translation:Humans
    90. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590; PMCID: PMC2562877.
      Citations: 9     Fields:    Translation:Humans
    91. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203. PMID: 18490922; PMCID: PMC2562662.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    92. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41. PMID: 18362942; PMCID: PMC2361701.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    93. Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J. 2008 Jan-Feb; 14(1):35-9. PMID: 18303481.
      Citations: 8     Fields:    Translation:HumansCells
    94. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8. PMID: 17948916.
      Citations: 4     Fields:    Translation:Humans
    95. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec; 70(6):1173-8. PMID: 18158041.
      Citations:    Fields:    Translation:Humans
    96. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. PMID: 17908974.
      Citations: 46     Fields:    Translation:Humans
    97. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007 Aug; 89(8):1794-801. PMID: 17671020.
      Citations: 62     Fields:    Translation:Humans
    98. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007 Jul; 5(7):675-84. PMID: 17634423; PMCID: PMC2000833.
      Citations: 19     Fields:    Translation:HumansCells
    99. Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci. 2007 May 01; 12:3273-86. PMID: 17485298.
      Citations: 19     Fields:    Translation:Humans
    100. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol. 2007 Apr; 177(4):1330-4; discussion 1334. PMID: 17382725.
      Citations: 26     Fields:    Translation:Humans
    101. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J. 2007 Apr; 29(4):813-5. PMID: 17400880.
      Citations: 3     Fields:    Translation:Humans
    102. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan 15; 109(2):198-204. PMID: 17171704.
      Citations: 30     Fields:    Translation:Humans
    103. Tuziak T, Spiess PE, Abrahams NA, Wrona A, Tu SM, Czerniak B. Multilocular cystadenoma and cystadenocarcinoma of the prostate. Urol Oncol. 2007 Jan-Feb; 25(1):19-25. PMID: 17208134.
      Citations: 2     Fields:    Translation:Humans
    104. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan; 177(1):131-8. PMID: 17162023.
      Citations:    Fields:    Translation:HumansPHPublic Health
    105. Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev. 2006 Dec; 25(4):601-9. PMID: 17160554.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    106. Pagliaro LC, Perez CA, Tu SM, Daliani DD. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol. 2006 Nov-Dec; 24(6):487-91. PMID: 17138128.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    107. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006 Oct 01; 107(7):1503-10. PMID: 16944534.
      Citations: 7     Fields:    Translation:Humans
    108. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 01; 107(7):1483-90. PMID: 16944541.
      Citations: 7     Fields:    Translation:Humans
    109. Tu SP, Taylor V, Yasui Y, Chun A, Yip MP, Acorda E, Li L, Bastani R. Promoting culturally appropriate colorectal cancer screening through a health educator: a randomized controlled trial. Cancer. 2006 Sep 01; 107(5):959-66. PMID: 16865681.
      Citations: 73     Fields:    Translation:HumansPHPublic Health
    110. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505. PMID: 16795067.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    111. Seng P, Acorda E, Carey Jackson J, Marchand A, Thai H, Tu SP, Taylor V. AANCART best practices: cancer awareness activities for Seattle's Combodian community. Cancer. 2005 Dec 15; 104(12 Suppl):2916-9. PMID: 16276540; PMCID: PMC1811046.
      Citations:    Fields:    Translation:Humans
    112. Tu SP, Chen H, Chen A, Lim J, May S, Drescher C. Clinical trials: understanding and perceptions of female Chinese-American cancer patients. Cancer. 2005 Dec 15; 104(12 Suppl):2999-3005. PMID: 16247796; PMCID: PMC1810650.
      Citations: 34     Fields:    Translation:Humans
    113. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10. PMID: 16258090.
      Citations: 16     Fields:    Translation:Humans
    114. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004 Jun 01; 22(11):2108-21. PMID: 15169797.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    115. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol. 2004 Jun; 203(2):688-95. PMID: 15141384.
      Citations: 16     Fields:    Translation:HumansCells
    116. Tu SM, Lin SH. Clinical aspects of bone metastases in prostate cancer. Cancer Treat Res. 2004; 118:23-46. PMID: 15043187.
      Citations: 5     Fields:    Translation:Humans
    117. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol. 2003 Sep-Oct; 21(5):342-8. PMID: 14670540.
      Citations:    Fields:    Translation:Humans
    118. Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2003 Aug 06; 95(15):1174-5; author reply 1175. PMID: 12902452.
      Citations:    Fields:    Translation:Humans
    119. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003 Aug 01; 98(3):504-7. PMID: 12879466.
      Citations: 19     Fields:    Translation:Humans
    120. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer. 2003 Jun 15; 97(12):2988-94. PMID: 12784333.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    121. Tu SP, Yasui Y, Kuniyuki AA, Schwartz SM, Jackson JC, Hislop TG, Taylor V. Mammography screening among Chinese-American women. Cancer. 2003 Mar 01; 97(5):1293-302. PMID: 12599238; PMCID: PMC1618781.
      Citations: 25     Fields:    Translation:Humans
    122. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer. 2003 Feb 01; 97(3 Suppl):785-8. PMID: 12548576.
      Citations: 3     Fields:    Translation:Humans
    123. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 01; 97(3):561-7. PMID: 12548597.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    124. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol. 2003 Jan-Feb; 21(1):21-6. PMID: 12684123.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    125. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002 Aug; 3(8):508-13. PMID: 12147437.
      Citations: 63     Fields:    Translation:HumansCells
    126. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15; 20(14):3072-80. PMID: 12118020.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    127. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002 Jul 01; 20(13):2965-70. PMID: 12089226.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    128. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60. PMID: 12085204; PMCID: PMC2746595.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    129. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7. PMID: 12173328.
      Citations: 41     Fields:    Translation:Humans
    130. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002 Mar 01; 20(5):1361-7. PMID: 11870180.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    131. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001 Aug; 166(2):521-5. PMID: 11458058.
      Citations: 49     Fields:    Translation:Humans
    132. Park DS, Vassilopoulou Sellin R, Tu S. Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases. Urology. 2001 Jul; 58(1):105. PMID: 11445494.
      Citations: 1     Fields:    Translation:Humans
    133. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 03; 357(9253):336-41. PMID: 11210994.
      Citations: 87     Fields:    Translation:HumansCTClinical Trials
    134. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000 Aug 01; 89(3):615-8. PMID: 10931461.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    135. Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int J Mol Med. 1998 Jun; 1(6):953-9. PMID: 9852630.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    136. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201. PMID: 9607577.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    137. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998 Mar; 159(3):792-5. PMID: 9474150.
      Citations: 10     Fields:    Translation:Humans
    138. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 01; 80(11):2128-32. PMID: 9392335.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    139. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2371-6. PMID: 9815636.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    140. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500. PMID: 9815652.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    141. Westin P, Lo P, Marin M, Fernandez A, Sarkiss M, Tu S, Brisbay S, Voneschenbach A, McDonnell T. bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. Int J Oncol. 1997 Jan; 10(1):113-8. PMID: 21533353.
      Citations:    Fields:    
    142. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996 Nov-Dec; 2(6):191-7. PMID: 21224168.
      Citations: 5     Fields:    
    143. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995 Nov; 154(5):1719-22. PMID: 7563331.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    144. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol. 1995 Sep; 13(9):2272-7. PMID: 7666085.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    145. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, McDonnell TJ. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett. 1995 Jul 13; 93(2):147-55. PMID: 7621422.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    146. McDonnell TJ, Marin MC, Hsu B, Brisbay SM, McConnell K, Tu SM, Campbell ML, Rodriguez-Villanueva J. The bcl-2 oncogene: apoptosis and neoplasia. Radiat Res. 1993 Dec; 136(3):307-12. PMID: 8278571.
      Citations: 6     Fields:    Translation:HumansAnimals
    147. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett. 1992 Aug 31; 65(3):215-20. PMID: 1355405.
      Citations: 12     Fields:    Translation:Humans
    148. Deckmyn H, Tu SM, Majerus PW. Guanine nucleotides stimulate soluble phosphoinositide-specific phospholipase C in the absence of membranes. J Biol Chem. 1986 Dec 15; 261(35):16553-8. PMID: 3023354.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    149. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer. PLoS One. 10.
    150. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Annals of Oncology. 26:2125-2132.
    151. Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation. Clinical Genitourinary Cancer.
    152. Expression of bcl-2 and its correlation with the development of androgen independent. Cancer Bulletin. 45:448-452.
    153. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi. Annals of Oncology. 26:2507-2508.
    154. Radium-223. ONCOLOGY (United States). 29.
    155. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical Genitourinary Cancer.
    156. Intratumoral heterogeneity. Cancer.
    157. Phase I-II study of Gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 12:365-370.
    158. Postacute Care in Cancer Rehabilitation. Physical Medicine and Rehabilitation Clinics of North America. 28:19-34.
    159. Corrigendum. Cancer Letters. 99:247.
    160. Stem cells in carcinogenesis of the prostate. 73-79.
    161. Editorial comment. Canadian Journal of Urology. 19:6268.
    162. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    163. Clinically atypical seminomas with yolk sac tumor features. Canadian Journal of Urology. 20:6860-6867.
    164. A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. Urologic Oncology: Seminars and Original Investigations. 1:156-160.
    165. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 4.
    TU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (496)
    Explore
    _
    Co-Authors (123)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _